ABSTRACT
INTRODUCTION
Hepatitis C virus (HCV) infection is an important infectious disease which can cause chronic liver disease, cirrhosis, and hepatocellular carcinoma. There are seven genotypes and more than 80 subtypes of HCV. The various genotypes and subtypes of HCV are associated with different geographical patterns. HCV genotype 1 is the most frequent genotype in Turkey. The prevalence of genotype 4 in Kayseri, a city in Middle Anatolia in Turkey, is higher than the average national HCV genotype distribution. 1 In previous studies, it has been shown that genotypes 1 and 4 are more resistant than genotypes 2 and 3 to combination therapy. 2 HCV genotype determination is very important for selecting antiviral therapy, deciding on treatment duration and monitoring response to treatment. In addition, HCV genotyping is an important and essential tool for epidemiological studies and for tracing the source of infection. [3] [4] [5] DNA sequence analysis is the gold standard method for HCV genotyping and is used in most laboratories. Recently, several methods targeting different regions of the HCV genome have been used for genotyping, such as: serologically-based methods, line probe assay, allele-specific PCR, and restriction fragment length polymorphism. [6] [7] [8] [9] The Versant HCV Genotype 2.0 assay (INNO-LIPA HCV v.2.0, France) is based on the reverse hybridization of the 5´UTR region and core region. 10 Pyrosequencing assay is a real-time quantitative sequencing analysis technique based on detection of pyrophosphate released during DNA synthesis.
11
The Abbott Real Time HCV Genotype II assay (Abbott, USA) targets the 5´UTR region, which is highly conserved among HCV genotypes, and the NS5B gene for efficient discrimination between HCV genotypes 1a and 1b. 12 The aim of this study was to evaluate the performance of Abbott Real Time HCV Genotype II assay in HCV genotyping of HCV infected patients in Kayseri, a city in Middle Anatolia in Turkey. HCV genotypes 4 and 3 were found to be subtype 4d and 3a, respectively, by sequence analysis. There were four patients with genotype 2. According to sequence analysis, two of these patients had subtype 2a and two had subtype 2b. In addition, genotypes 1 and 4 require prolonged treatment compared to genotypes 2 and 3.
METHODS

Patients
13, 15 Patients infected with HCV genotype 1 and 4 require 48 weeks of treatment, while patients with genotype 2 and 3 require 24 weeks of treatment.
In Turkey, the most common genotype is genotype 1b, followed by genotype 1a. Genoypes 2a, 3a, 4, 4c occur at lower rates. [16] [17] [18] However, in Kayseri, a city in Middle Anatolia in Turkey, the second most common genotype is 4. 1, 19 The phylogenetic analysis showed that HCV genotype 4d samples in this region were in 82 -95% similarity with genotype 4d strains of different geographical regions. Genotype 4d strains are thought to have come to this region 30 -75 years ago according to molecular clock analysis. 20 Direct sequence analysis is a method widely used for genotyping. 7, 8 However, there are many disadvantages of sequence analysis. For example, it is expensive, time-consuming, and requires experienced staff. 11 For this reason, semi-automated systems are widely used. The Abbott Real Time HCV Genotype II assay, based on genotype specific real time PCR, has been widely used to analyze HCV genotypes. 1, 6, 12, 21, 22 Earlier studies reported that the patients with subtype 1b have a worse prognosis than patients with subtype 1a. As genotype 1 is the most common genotype in Turkey, as well as in many other countries, subtyping is important. Ciotti et al. 12 evaluated the performance of the Abbott Real Time HCV Genotype II assay and the Versant HCV Genotype 2.0 assay, and reported that there was good agreement between the two assays. Yang et al. 21 showed that Abbott Real Time HCV Genotype II assay and Versant HCV genotype 2.0 assay have limitations in identifying HCV genotype 6. However, in our study we did not find any genotype 6 by either Abbott Real Time HCV Genotype II assay or sequence analysis.
Limitations of the study: There are some limitations in our study, such as limited sample size and lack of mixed genotypes.
CONCLUSION
Concordance between the Abbott Real Time HCV genotype II assay and sequence analysis for determining of major HCV genotypes was good in this study. Although the Abbott Real Time HCV genotype II assay has the additional advantages of automation, rapidity and low labour intensity, we suggest that this system needs improvement for subtype identification of HCV.
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